Atomoxetineinteractions

atomoxetine 100 MG Oral Capsule

This is the interactions section of this product’s FDA label — what the manufacturer documented for this drug. It is not a check of your medication list, and a drug missing from it has not been cleared: licensed clinical databases list far more interactions than any single label does. Before combining medicines, ask a pharmacist, who can check everything you take at once and will do it for free.

Named on this label

Every name above is printed in the text below. This is not the full set of drugs that interact with this one — it is the set this manufacturer wrote down.

Drug interactions

Monoamine Oxidase Inhibitors: Concomitant use contraindicated.

Strong CYP2D6 Inhibitors: With concomitant use of atomoxetine capsules and strong CYP2D6 inhibitors, increase the titration intervals.

Antihypertensives: Increase the frequency of monitoring blood pressure and adjust atomoxetine capsules dosage as clinically appropriate. Albuterol (or other beta2 agonists): Increase the frequency of monitoring blood pressure and heart rate. See Table 8 for clinically significant drug interactions with atomoxetine and other drugs.

Table 8: Clinically Significant Drug Interactions with Atomoxetine and Other Drugs Monoamine Oxidase Inhibitors (MAOIs) Prevention or Management Atomoxetine is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue, or in patients who stopped an MAOI within 14 days. Mechanism and Clinical Effect(s) As with other drugs affecting brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (hyperthermia, rigidity, myoclonus, autonomic instability with fluctuations of vital signs, extreme agitation progressing to delirium/coma) with concomitant use of atomoxetine and an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Strong CYP2D6 Inhibitors Prevention or Management With concomitant use of atomoxetine and a strong CYP2D6 inhibitor, increase the titration interval. Mechanism and Clinical Effect(s) Atomoxetine is a CYP2D6 substrate. The concomitant use of atomoxetine and a strong CYP2D6 inhibitor increases atomoxetine exposure. Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine dosage as clinically appropriate. Mechanism and Clinical Effect(s) Because of increased risk of increased blood pressure, atomoxetine should be used cautiously with antihypertensive drugs, other drugs that increase blood pressure or pressor drugs (e.g., dopamine, dobutamine). Albuterol or Other Beta2 Agonists Prevention or Management Increase the frequency of monitoring blood pressure and heart rate and adjust atomoxetine dosage as clinically appropriate. Mechanism and Clinical Effect(s) Systemically administered albuterol (e.g., oral) can be potentiated by atomoxetine, resulting in increases in heart rate and blood pressure.

Text above is quoted in full from the FDA-approved drug label published by openFDA, effective August 11, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.

This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.

See what it costs — price without insurance